Pay in 4 interest-free payments of $6.27 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
The SURMOUNT-1 trial (Jastreboff et al., NEJM 2022) is the landmark efficacy data: tirzepatide at 15mg weekly produced 22.5% average body weight reduction over 72 weeks in adults with obesity without diabetes the highest weight reduction ever documented in a pharmaceutical trial
Their focus was on adult patients with diabetes and obesity and those who had been diagnosed with acute pancreatitis
Ivim Health requires enhanced testing including endotoxin screening, extended stability studies, and third-party verification before medication distribution
PMID: 28492874
N Engl J Med 392:427437 le Roux CW, Astrup A, Fujioka K et al (2017) 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial
